Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 12/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30017714 | 1.00 | POLQ (0.48) | POLQKDM4EMAPTTSHRDHFR | |
| SCHEMBL30017624 | 0.90 | POLQ (0.51) | POLQKDM4EDHFRPRKAG1PRKAA1 | |
| SCHEMBL24770955 | 0.90 | POLQ (0.51) | POLQKDM4EDHFRPRKAG1PRKAA1 | |
| SCHEMBL24770271 | 0.89 | POLQ (0.49) | POLQDHFR | |
| SCHEMBL24769644 | 0.84 | POLQ (0.63) | POLQKDM4EDHFR | |
| SCHEMBL31032138 | 0.84 | POLQ (0.63) | POLQKDM4EDHFR | |
| SCHEMBL30017674 | 0.79 | POLQ (0.45) | POLQKDM4EDHFRPRKAG1PRKAA1 | |
| SCHEMBL24769388 | 0.79 | POLQ (0.45) | POLQKDM4EDHFRPRKAG1PRKAA1 | |
| SCHEMBL24769961 | 0.79 | POLQ (0.79) | POLQ | |
| SCHEMBL30017048 | 0.79 | POLQ (0.79) | POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED (GB) | 2024-08-29 | — | — | US | disclosed |
| EP-4352055-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | Ideaya Biosciences, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022259204-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
| WO-2022259204-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287080-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | POLQ, POLK, POLB | POLQ 1/4885KDM4E 3720/4885MAPT 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.